AQST – Aquestive Therapeutics: Anaphylm after the CRL and what 2025 results really tell us

1. Executive summary – What changed with these earnings

The March 4, 2026 earnings release does not transform Aquestive’s story, but it does re-anchor expectations after the shock of the January CRL. The key messages are: revenue is growing modestly from manufacturing contracts, operating expenses have surged as Anaphylm launch spending and legal costs hit the P&L, the balance sheet – strengthened by capital raises in 2024–2025 – still supports a multi-year push towards approval, and RTW has just amended its revenue-sharing agreement to extend the approval deadline to June 30, 2027 while taking incremental equity risk.

On the regulatory front, the CRL is explicitly framed as a human-factors and packaging issue. The FDA did not question the comparative PK/PD data versus auto-injectors, did not request new large clinical trials, and did not raise chemistry, manufacturing or controls flags. The resubmission plan – a new human-factors validation study plus a PK study, potentially run in parallel – is ambitious but conceptually straightforward. The company is guiding towards a Q3 2026 resubmission and intends to request accelerated review, while also preparing Canadian and EU filings for Anaphylm.

Financially, 2025 shows the cost of “running for approval”: total revenues of 44.5M $ (largely manufacturing and supply), R&D cut back to 17.2M $, but SG&A inflated to almost 80M $ once one-time legal expenses and the PDUFA fee are included. The full-year net loss reaches 83.8M $, and even on a Non-GAAP adjusted EBITDA basis the loss widens to 49.7M $, reflecting both pre-launch spending and the legal settlement. Management guides to 46–50M $ revenue and a 30–35M $ adjusted EBITDA loss in 2026, with cash expected to decline from 121.2M $ at year-end 2025 to about 70M $ at year-end 2026.

The big picture is a familiar one for small-cap biotech investors: a company with a commercially validated film technology, some steady but limited manufacturing revenue, a flagship asset with a clearly addressable regulatory to-do list, and a balance sheet that can carry the story through the next major catalyst but leaves little room for major mis-steps. The RTW amendment is a vote of confidence but also a reminder that partners are closely tracking timelines and economics. For risk-tolerant investors, AQST remains a leveraged bet on the eventual regulatory and commercial success of Anaphylm as the first oral epinephrine rescue product.

2. Business model, products and pipeline

2.1 – PharmFilm platform and manufacturing base

Aquestive’s core technology is its film-based drug delivery platform, historically commercialized via collaborations (Suboxone, Sympazan, Ondif, Emylif, Azstarys). In 2025 the company manufactured about 47 million doses in Q4, up from 43 million in the prior-year quarter, with Suboxone gradually declining and newer partners offsetting that erosion. This steady manufacturing base translates into roughly 40M $ of annual manufacture & supply revenue, which underpins a portion of the cost structure but is far from sufficient to support the current R&D and pre-launch spend on its own.

Royalty-driven products like Sympazan and Azstarys add another, smaller layer of relatively predictable income. The earnings release emphasizes that the company’s supply chain remains largely unaffected by tariffs and that its intellectual property is domiciled in the US, a useful but incremental positive.

2.2 – Anaphylm (epinephrine sublingual film)

Anaphylm is designed as a compact, polymer-matrix epinephrine prodrug film that dissolves under the tongue without the need for water or swallowing. The primary target indication is the emergency treatment of Type I allergic reactions – including anaphylaxis – in patients weighing 30 kg or more. The trade name has been conditionally approved, pending full FDA approval of the product. The narrative is straightforward: people at risk of anaphylaxis often dislike needles, may delay or avoid using auto-injectors, and struggle with carrying bulkier devices; a pocket-sized, non-invasive film could increase adherence and real-world use in emergencies.

The CRL issued on January 30, 2026 did not challenge the pharmacology of the product. Instead, the FDA highlighted human-factors concerns around pouch opening and film placement, and requested a dedicated PK study to assess the impact of packaging and labeling modifications. From a risk-management standpoint this matters: it suggests that, at least based on current information, the “barrier to approval” is about device-use behaviour and labelling rather than underlying efficacy or safety.

2.3 – Libervant and the epilepsy franchise

Libervant, diazepam buccal film for seizure clusters, technically has FDA approval in certain age groups but is stuck in a long-running orphan exclusivity dispute: the agency converted the approval to “tentative approval” because of exclusivity granted to a competing intranasal spray. Under the current legal framework, Libervant cannot access the US market until that exclusivity expires in January 2027. Aquestive continues to view Libervant as an important long-term asset – especially as prescribers and families seek non-invasive rescue alternatives to rectal formulations – but investors should treat any Libervant-driven revenue before 2027 as unlikely.

2.4 – AQST-108 topical gel and the Adrenaverse platform

AQST-108 is a topical epinephrine prodrug gel being explored for alopecia areata, a chronic autoimmune condition with an estimated 6.7 million affected individuals in the US, many of them with severe disease. Current systemic treatments, mainly JAK inhibitors, can be effective but come with boxed warnings and substantial cost. Aquestive’s thesis is that a locally acting topical epinephrine prodrug, if it truly acts at the site of application with limited systemic exposure, might offer a differentiated safety and convenience profile.

The company has opened an IND for AQST-108, completed a first-in-human study without serious or topical adverse events, and finished dosing in a second Phase 1 trial in Q1 2026, with data expected in Q2 2026. At this stage AQST-108 remains an early, option-like asset; the key inflection point will be whether Phase 1 data support continued development in alopecia and potentially other dermatologic indications.

3. Financials – 2025 in numbers and what 2026 guidance really implies

3.1 – Q4 and full-year 2025: growth in manufacturing, heavy spend on launch & legal

Q4 2025 revenue grew about 10% year-on-year to 13.0M $, driven mainly by manufacture and supply revenue climbing from 10.7M $ to 12.0M $. On a full-year basis, revenue appears to drop from 57.6M $ to 44.5M $, but that headline figure is distorted by the one-time recognition of deferred revenue in 2024 following the termination of licensing and supply agreements. Excluding that one-off, 2025 revenue is down a modest 3% (1.5M $), essentially flat given the moving parts.

R&D spend decreased from 20.3M $ in 2024 to 17.2M $ in 2025, reflecting the transition from heavy Anaphylm clinical trial spending to a more focused development and regulatory-support phase. This is not “de-risking” in the strict sense – Anaphylm is not yet approved – but it indicates that the most expensive parts of the initial clinical program are behind the company.

SG&A is where 2025 hurts. Excluding one-time legal expenses, SG&A jumped from 50.2M $ to 66.6M $; including legal, it surged to 79.8M $. The drivers are illustrative: approximately 14.3M $ in higher legal expenses, 9.6M $ in heavier commercial spending in preparation for the planned Anaphylm launch, a 4.3M $ PDUFA fee, plus higher personnel and regulatory expenses. The Neurelis legal settlement, while confidential, clearly contributed to the spike.

As a result, net loss widened sharply. Excluding one-time legal costs, the company lost 70.6M $ in 2025 (0.66 $ per share), versus 44.1M $ in 2024. Including legal, the loss reached 83.8M $ (0.78 $ per share). Non-GAAP adjusted EBITDA loss, a rough proxy for cash operating performance, more than doubled from 23.0M $ to 49.7M $.

3.2 – Cash runway, RTW agreement and 2026 guide

The positive counterweight is the balance sheet. Cash and cash equivalents at December 31, 2025 stood at 121.2M $. Management now guides to end 2026 with around 70M $, after absorbing the cost of the human-factors and PK studies, continued pre-commercial infrastructure spending for Anaphylm, and regulatory work for Canada and the EU. Importantly, the guidance specifically states that it does not include costs for a full-scale commercial launch of Anaphylm, if approved; those would come on top and would likely require either reallocation of spend, additional financing, or both.

The amended agreement with RTW is central to the financial narrative. By extending the Anaphylm approval deadline in the revenue-sharing arrangement to June 30, 2027, RTW effectively accepts the new regulatory timeline and stays in the game. The warrant for up to 375k shares at 4.00 $ (expiring in 2029) and the 5M $ share purchase commitment over 90 days indicate a willingness to incrementally support the equity, even as RTW keeps economic exposure to eventual Anaphylm revenue.

From a runway perspective, the combination of 121M $ in cash, a guidance to about 70M $ at the end of 2026, and the RTW backstop (together with any ATM flexibility) suggests that AQST can reasonably fund itself through the Q3 2026 resubmission and well into the subsequent review period. However, with adjusted EBITDA still guided at -30 to -35M $, the margin for error is not huge. Any delays, cost overruns, or external shocks could reopen the dilution debate sooner than the company or investors would like.

3.3 – What the 2026 guide tells us about management’s priorities

The 2026 outlook is intentionally conservative on revenue – a slight uptick from 44.5M $ to 46–50M $ – and explicit about continued negative adjusted EBITDA. This is not a “path to profitability” slide; it is a “fund the resubmission and keep the commercial machine warm” slide. In other words, management is choosing to protect optionality on a future Anaphylm launch rather than aggressively cutting SG&A to minimize losses.

For equity holders, that choice can be interpreted in two ways. Bulls will argue that maintaining the commercial infrastructure and pushing forward on global filings increases the chance that, once Anaphylm is approved, AQST can capture meaningful market share quickly. Bears will counter that the company is essentially “burning runway” in the hope that the timeline plays out as guided, exposing shareholders to the risk of raising capital in a bad tape.

4. Regulatory path from the CRL to a potential approval

4.1 – Anatomy of the CRL: what is not the problem

The CRL’s wording is unusually reassuring on some fronts. The FDA explicitly did not question the chemistry, manufacturing and controls package and did not raise objections to the comparative data versus established auto-injectors. Instead, the document focuses on human-factors validation (pouch opening and film placement) and on the need for a PK study that captures the impact of packaging and labeling modifications. No new large pivotal trials are requested, and the agency notes that the HF and PK work can run in parallel.

In practical terms, this means that the regulatory task in front of Aquestive is to generate robust, real-world-like evidence showing that Anaphylm can be reliably used by patients and caregivers under stress, with clear instructions and minimal risk of misuse. For investors, it reframes the risk: the question becomes “can the company design and execute the HF and PK program properly and on time?” rather than “does the drug work?”.

4.2 – Timeline: Type A meeting, HF + PK studies, Q3 2026 resubmission

The company has already requested a Type A meeting with the FDA to agree on the most efficient path to resubmission. The plan is to run a new human-factors validation study, aligned with the agency’s expectations, and a PK study examining the final packaging and labelling configuration. Assuming the meeting confirms that the proposed design is adequate, AQST believes it can complete the work and resubmit the NDA in Q3 2026.

Upon resubmission, Aquestive intends to request an accelerated review, given the nature of Anaphylm and the unmet need in non-invasive epinephrine administration. However, the FDA is not bound to grant priority review, and the ultimate PDUFA timing will depend on both the content of the resubmission and the agency’s priorities at that time.

4.3 – Global strategy: Canada and EU

In parallel, the company is preparing regulatory filings for Anaphylm in Canada and the European Union during 2026. These markets differ in size, reimbursement mechanics and competitive landscape, but they share the underlying need for more convenient, reliable emergency treatments for severe allergic reactions. A multi-leg regulatory strategy adds complexity but also diversifies the potential revenue base if the US pathway goes according to plan.

5. Sentiment – How non-professional traders and analysts are reading AQST

5.1 – Retail channels (Reddit, Stocktwits, X)

In the weeks around the CRL and the earnings release, discussions on Reddit, Stocktwits and X have been highly polarized. On one side, there is a vocal group treating the CRL as “only packaging and human factors”, pointing to the absence of CMC or efficacy issues and highlighting the Q3 2026 resubmission guide as evidence that the damage is fixable. Some posters openly describe the stock as a high-conviction “overreaction” trade after the post-CRL sell-off, with target prices anchored to pre-CRL levels or to analyst targets in the high-single-digit range.

On the other side, many retail traders emphasize the pattern: a small-cap biotech with a history of losses, repeated capital raises and binary catalysts that frequently end up in sharp drawdowns for late entrants. In those threads the focus shifts from “will Anaphylm eventually be approved?” to “how much dilution will it take, and will I be able to exit at a profit even if approval happens?” This is especially visible in comments from holders who bought closer to the highs near 7–8 $ and are now facing heavy paper losses.

Importantly, sentiment indicators on some trading platforms flipped to “extremely bullish” precisely on days when the stock was suffering large drawdowns, reflecting the tendency of momentum-driven traders to add risk into volatility. For long-term investors, that mix of enthusiasm and fear underlines the need for position sizing and for a clear personal risk budget.

As always, comments and “DD” on these channels come from non-professional traders and should be treated as opinions, not as investment advice. They are useful to understand positioning and mood, not to replace independent analysis.

5.2 – Street view and target ranges

On the sell-side, coverage remains limited but broadly constructive: several firms maintain Outperform / Overweight ratings with target prices clustered in the mid- to high-single-digit range, sometimes higher, reflecting the perceived upside if Anaphylm becomes a meaningful player in the epinephrine market. The 2025–2026 sequence of capital raises, the CRL and the RTW amendment have led to model adjustments – especially on timelines and peak-sales curves – but the core thesis remains: a first-in-class oral epinephrine rescue product addressing a large and psychologically under-treated market.

6. Scenarios, key risks and monitoring checklist

6.1 – Simplified scenario map (qualitative)

A simplified way to think about AQST after these earnings is to frame three broad scenarios:

• Constructive base case – The Type A meeting confirms a clear, executable HF/PK plan; studies run broadly on time; the NDA is resubmitted in Q3 2026; review proceeds without major surprises and, within the extended RTW deadline, Anaphylm secures approval with a usable label. Manufacturing revenue continues to support the base, Libervant moves closer to its 2027 window, and AQST-108 generates at least one credible Phase 1 signal. Under this path, the debate shifts to adoption curves, pricing and reimbursement.
• Bearish execution case – Delays or issues in HF or PK studies, more extensive FDA feedback than anticipated, or negative surprises in alopecia or other pipeline elements extend the timeline beyond what the current cash and RTW framework comfortably support. The company then faces difficult choices on spending, potential partnering and equity issuance, with existing shareholders absorbing the cost.
• Upside optionality case – Beyond the base case, upside comes from faster-than-expected adoption in allergy (if the real-world convenience advantage proves powerful), a stronger-than-expected Libervant ramp post-2027, or clearly positive AQST-108 dermatology data opening a new franchise. In that world AQST morphs from a “serial hope trade” into a small but diversified CNS/allergy platform company.

6.2 – Concrete risk checklist

Key risks to track over the next 12–24 months include:

• Regulatory risk: any change in FDA communication that expands the list of required studies or raises new concerns beyond human-factors and packaging.
• Timing risk: slippage of the Type A meeting, HF/PK study start or completion, or resubmission timing beyond Q3 2026.
• Financing risk: market conditions at the time of any potential capital raises; ability to use ATM or structured equity without severely pressuring the share price.
• Commercial risk: even with approval, real-world uptake could be slower than the most optimistic projections if prescribers remain conservative, payers push back, or competing solutions evolve.